Kelly Michael Aaron, a director at NeoGenomics Inc. ($NEO), made one open market purchase of company shares in the last year, totaling $38,000. His most recent buy occurred on May 27, 2025. This places him 3,269th among nearly 5,000 insiders by purchase value, well below the average of 1.46 million per buyer across 3.29 transactions. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | D | Stock Option (right to buy) | 13510 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 13510 | $0.00 | 13,510.0000 | 131,160,842 | 9999.99% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | D | Stock Option (right to buy) | 9006 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 9006 | $0.00 | 9,006.0000 | 131,160,842 | 9999.99% | 0.01% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | D | Stock Option (right to buy) | 39062 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 131,160,842 | 9999.99% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | D | Stock Option (right to buy) | 45000 | $0.00 | 0.0000 | 131,160,842 | 100.00% | 0.03% |
| Aug. 1, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 131,160,842 | 9999.99% | 0.03% |
| June 5, 2025 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Not found | A | Common Stock | 20414 | $0.00 | 72,468.0000 | 300,116,081 | 39.22% | 0.01% |
| June 5, 2025 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Not found | A | Stock Options (right to buy) | 74872 | $0.00 | 74,872.0000 | 300,116,081 | 9999.99% | 0.02% |
| June 4, 2025 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 55000 | $0.00 | 55,000.0000 | 131,160,842 | 9999.99% | 0.04% |
| June 1, 2025 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | M | Restricted Stock Unit | 12254 | $0.00 | 0.0000 | 128,461,383 | 100.00% | 0.01% |
| June 1, 2025 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | A | Restricted Stock Unit | 23077 | $0.00 | 23,077.0000 | 128,461,383 | 9999.99% | 0.02% |
| June 1, 2025 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | A | Stock Option (Right to Buy) | 16107 | $0.00 | 33,132.0000 | 128,461,383 | 94.61% | 0.01% |
| June 1, 2025 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | M | Common Stock | 12254 | $0.00 | 49,009.0000 | 128,461,383 | 33.34% | 0.01% |
| May 27, 2025 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | P | Common Stock | 5000 | $7.60 | 36,755.0000 | 128,461,383 | 15.75% | 0.00% |
| May 14, 2025 | DMC Global Inc. | $BOOM | Kelly Michael Aaron | Director | A | Common Stock | 17580 | $0.00 | 48,653.0000 | 21,403,030 | 56.58% | 0.08% |
| Feb. 26, 2025 | DMC Global Inc. | $BOOM | Kelly Michael Aaron | Director | A | Common Stock | 5518 | $0.00 | 31,073.0000 | 21,083,184 | 21.59% | 0.03% |
| Aug. 10, 2024 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | M | Common Stock | 11336 | $0.00 | 31,755.0000 | 0 | 55.52% | 0.00% |
| Aug. 10, 2024 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | M | Restricted Stock Unit | 11336 | $0.00 | 12,254.0000 | 0 | 48.05% | 0.00% |
| June 12, 2024 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| June 6, 2024 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Not found | A | Common Stock | 11847 | $0.00 | 52,054.0000 | 295,164,515 | 29.47% | 0.00% |
| June 6, 2024 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Not found | A | Stock Options (right to buy) | 42467 | $0.00 | 42,467.0000 | 295,164,515 | 9999.99% | 0.01% |
| June 1, 2024 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | A | Restricted Stock Unit | 12254 | $0.00 | 23,590.0000 | 0 | 108.10% | 0.00% |
| June 1, 2024 | NEOGENOMICS INC | $NEO | Kelly Michael Aaron | Director | A | Stock Option (Right to Buy) | 8672 | $0.00 | 17,025.0000 | 0 | 103.82% | 0.00% |
| May 15, 2024 | DMC Global Inc. | $BOOM | Kelly Michael Aaron | Director | A | Common Stock | 9520 | $0.00 | 25,555.0000 | 20,704,004 | 59.37% | 0.05% |
| June 14, 2023 | Prime Medicine, Inc. | $PRME | Kelly Michael Aaron | Director | A | Stock Option (right to buy) | 39062 | $0.00 | 39,062.0000 | 0 | 9999.99% | 0.00% |
| June 8, 2023 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Director | A | Common Stock | 8584 | $0.00 | 40,207.0000 | 289,057,198 | 27.14% | 0.00% |
| June 8, 2023 | AMICUS THERAPEUTICS, INC. | $FOLD | Kelly Michael Aaron | Director | A | Stock Options (right to buy) | 30474 | $0.00 | 30,474.0000 | 289,057,198 | 9999.99% | 0.01% |
| May 10, 2023 | DMC Global Inc. | $BOOM | Kelly Michael Aaron | Director | A | Common Stock | 7086 | $0.00 | 16,035.0000 | 20,140,654 | 79.18% | 0.04% |